Resistant Hypertension

As one of the most common chronic diseases in the world, hypertension affects about one third of adults worldwide. China has more than 330 million hypertensive patients, ranking first in the world. The results of the China Hypertension Survey show that the prevalence of hypertension in adults aged 18 and above is 27.9%, with an overall increasing trend. In addition, about 50% of cardiovascular morbidity and 20% of cardiovascular morality in China are attributed to hypertension. Despite the availability of a few safe and effective antihypertensive drugs, the overall rate of well-controlled hypertension is disappointing. In particular, resistant hypertension is poorly controlled with medications.

Solution

Resistant Hypertension

Solution

RDN Therapy

The principle of renal denervation (RDN) for the treatment of hypertension is to ablate sympathetic nerves in the walls of renal arteries and disrupt nerve signaling to lower blood pressure. Clinical studies have demonstrated the significant safety and efficacy of RDN therapy in the treatment of uncontrolled or resistant hypertension. Patients with resistant hypertension tend to benefit the most from RDN. At the same time, RDN provides an alternative for hypertensive patients with a poor compliance with oral drugs.

In June 2021, Venus Medtech announced Renaly Ltd., a joint venture with Healium Medical Ltd., to introduce next-generation innovative RDN devices and expand the R&D, manufacturing, and marketing of RDN products on a global scale. Healium Medical is an Israeli high-tech company dedicated to researching and developing the therapeutic and imaging capabilities of ultrasound energy. The partnership will expand the portfolio of solutions Venus Medtech offers in important ways. RDN products will create synergies with the existing structural heart disease product line to extend more therapeutic options for global patients suffering from hypertension.